(NYSE:AMWL), BOSTON , Nov. 04, 2025 (GLOBE NEWSWIRE) — Amwell(R) (NYSE: AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, today announced financial results for the third quarter ended September 30. The company's third quarter earnings report may be viewed at investors.amwell.com. Amwell will host a conference call to discuss its […]
(NASDAQ:TTSH), MINNEAPOLIS, Nov. 04, 2025 (GLOBE NEWSWIRE) — Tile Shop Holdings, Inc. (Nasdaq: TTSH) (the “Company”), a specialty retailer of natural stone, man-made and luxury vinyl tiles, today announced results for its third quarter ended September 30, 2025. Third Quarter 2025 Summary Net Sales Decreased 1.7%Comparable Store Sales Decreased 1.4% Gross Margin of 62.9%Net Loss
(NASDAQ:WEYS), Milwaukee, Wisconsin—November 4, 2025—Weyco Group, Inc. (NASDAQ: WEYS) (the “Company”) announced that today its Board of Directors declared a special cash dividend of $2.00 per share. The Company's total cash outlay for this special dividend will be approximately $19 million. The dividend will be paid on January 9, 2026, to shareholders of record at
(NASDAQ:INNV), DENVER, Nov. 04, 2025 (GLOBE NEWSWIRE) — InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to frail, predominantly dual-eligible seniors through the Program of All-inclusive Care for the Elderly (PACE), today announced financial results for its fiscal first quarter ended September 30, 2025. “We're off
(NASDAQ:LFVN), SALT LAKE CITY, Nov. 04, 2025 (GLOBE NEWSWIRE) — LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today reported financial results for its first fiscal quarter ended September 30, 2025. First Quarter Fiscal 2026 Summary*: Revenue was $47.6 million, an
(NasdaqGM:IMRX), – New case studies on first-line pancreatic cancer patients treated with atebimetinib in combination with FOLFIRINOX to be shared by trial investigators – – Conference call scheduled for Wednesday, November 12, 2025, at 4:30 pm ET – NEW YORK, Nov. 04, 2025 (GLOBE NEWSWIRE) — Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused
(NASDAQ:WEYS), MILWAUKEE, Nov. 04, 2025 (GLOBE NEWSWIRE) — Weyco Group, Inc. (NASDAQ: WEYS) (“we,” “our,” “us” and the “Company”) today announced financial results for the quarter ended September 30, 2025. Third Quarter 2025 Overview Net sales: $73.1 million (down 2% from $74.3 million in Q3 2024) Gross earnings: 40.7% of net sales (compared to 44.3%
(NASDAQ:POOL), COVINGTON, La., Nov. 04, 2025 (GLOBE NEWSWIRE) — Pool Corporation (Nasdaq: POOL) announced today that it will participate in the following investor events in November 2025: November 11, 2025 – Baird 2025 Global Industrial Conference November 18, 2025 – Stephens Annual Investment Conference Investor-related materials and company information are available on the Investor Relations
(NasdaqGM:TARA), NEW YORK, Nov. 04, 2025 (GLOBE NEWSWIRE) — Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that it has been named a BioSpace 2026 Best Place to Work. “Protara is thrilled to be recognized as one of the most sought-after biotech
(NASDAQ:OPRT), Meets or exceeds all third quarter guidance metrics GAAP Net income of $5.2 million reflects $35 million year-over-year improvement GAAP EPS of $0.11, up $0.86 versus prior-year period Adjusted EPS of $0.39, up sharply versus $0.02 in 3Q24 Operating expenses reduced 11% year-over-year, supporting continued margin expansion SAN CARLOS, Calif., Nov. 04, 2025 (GLOBE